NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will be presenting case histories on its recently launched i-Lid™ Cleanser with Neutrox™ at AAO 2014, the annual meeting of the American Academy of Ophthalmology in Chicago, October 18-21.
At the meeting, two prominent ophthalmologists, Eric Donnenfeld, MD and Kathryn Najafi-Tagol, MD, will describe their experiences using i-Lid Cleanser for chronic conditions such as blepharitis, meibomian gland dysfunction and for the preparation of patients undergoing surgical procedures of the eye.
Based on Long Island, Dr. Donnenfeld is an internationally recognized authority in the field of refractive, corneal and laser cataract surgery. Dr. Najafi-Tagol is Founder and Medical Director of the Eye Institute of Marin and co-developer of i-Lid Cleanser.
As Drs. Donnenfeld and Najafi-Tagol will explain, i-Lid Cleanser is the only commercially available eye care product to contain Neutrox—a proprietary form of pure hypochlorous solution (HOCl) developed and patented by NovaBay. Cleared by the US Food and Drug Administration as a wound cleanser, lab tests show that Neutrox, a naturally occurring substance released by white blood cells to fight microbial invaders, has potent antimicrobial activity in vitro, yet is non-toxic to healthy human cells. In solution, it also has been demonstrated in lab tests to neutralize bacterial toxins that can cause inflammation.
In their presentations, the doctors will discuss how i-Lid Cleanser is ideal as part of the management of common eyelid conditions, such as blepharitis, where Staphylcocci bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up that may ultimately result in Dry Eye Syndrome. Patients who’ve had blepharitis for years report along with their doctors that i-Lid Cleanser has finally brought them relief from this often-painful condition.
Additionally, many eye doctors are also now using i-Lid Cleanser routinely in preparation for cataract surgery and other types of surgery. Because Neutrox is not an antibiotic or steroid, there are minimal risks of bacterial resistance or side effects such as steroid induced glaucoma.
In addition to the presentation by Drs. Donnenfeld and Najafi-Tagol scheduled for October 19, NovaBay will be exhibiting its i-Lid Cleanser at its booth (Booth # 2573) during the entire conference. A full product presentation is also available by request from NovaBay.
“Conferences like AAO 2014 provide wonderful opportunities to talk about the benefits of Neutrox and i-Lid Cleanser,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “Once doctors hear about the results from using i-Lid Cleanser, we believe they will realize how much it can improve the management of many common eyelid conditions.”
This release contains forward-looking statements and opinions regarding the efficacy and commercial potential of i-Lid Cleanser, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The words “believe” and “will” are intended to identify the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to any possible unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
NovaBay i-Lid Cleanser Contacts (samples requests)
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson